MUSTACCHI, GIORGIO
 Distribuzione geografica
Continente #
EU - Europa 20.990
NA - Nord America 4.091
AS - Asia 437
Continente sconosciuto - Info sul continente non disponibili 20
SA - Sud America 12
AF - Africa 3
OC - Oceania 3
Totale 25.556
Nazione #
IT - Italia 18.914
US - Stati Uniti d'America 4.081
UA - Ucraina 385
FR - Francia 357
SE - Svezia 319
GB - Regno Unito 182
DE - Germania 160
CH - Svizzera 152
CN - Cina 127
FI - Finlandia 120
HK - Hong Kong 108
TR - Turchia 68
IE - Irlanda 64
SG - Singapore 63
BG - Bulgaria 62
PL - Polonia 43
RO - Romania 37
ES - Italia 30
AL - Albania 28
IN - India 24
NL - Olanda 24
BE - Belgio 22
EU - Europa 20
RU - Federazione Russa 15
IR - Iran 14
DK - Danimarca 12
GR - Grecia 11
PT - Portogallo 10
BR - Brasile 9
MY - Malesia 9
AT - Austria 8
CA - Canada 8
CZ - Repubblica Ceca 8
SI - Slovenia 6
SM - San Marino 6
IL - Israele 5
LU - Lussemburgo 4
CL - Cile 3
HR - Croazia 3
JP - Giappone 3
KR - Corea 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
GE - Georgia 2
MD - Moldavia 2
MT - Malta 2
NZ - Nuova Zelanda 2
AM - Armenia 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
CF - Repubblica Centrafricana 1
EG - Egitto 1
HU - Ungheria 1
IQ - Iraq 1
JM - Giamaica 1
LB - Libano 1
MX - Messico 1
NO - Norvegia 1
SN - Senegal 1
TH - Thailandia 1
TW - Taiwan 1
VA - Santa Sede (Città del Vaticano) 1
VN - Vietnam 1
Totale 25.556
Città #
Rome 1.030
Milan 972
Woodbridge 538
Ann Arbor 424
Fairfield 379
Jacksonville 340
Houston 330
Chandler 320
Naples 272
Ashburn 222
Wilmington 218
Florence 186
Seattle 182
Turin 175
Bologna 171
Palermo 152
Padova 141
Trieste 139
Napoli 138
Cambridge 132
Princeton 118
Torino 109
Hong Kong 108
Bari 105
Catania 89
Brescia 86
Genoa 83
Dallas 71
Cagliari 68
Verona 60
Dublin 59
Sofia 59
Izmir 57
Bergamo 54
Boardman 52
Perugia 51
Beijing 42
Caserta 42
Monza 42
Genova 41
Mountain View 41
Udine 41
Como 40
Messina 40
Singapore 40
Pescara 39
Venezia 37
Dearborn 36
Treviso 35
Vicenza 33
Reggio Calabria 32
Pisa 30
Sassari 30
Ancona 29
Taranto 29
Latina 28
San Diego 28
Lucca 27
Modena 26
Reggio Nell'emilia 26
Catanzaro 25
Parma 25
Pavia 23
Salerno 23
Bremen 22
Foggia 22
Livorno 22
Redwood City 22
Venice 22
Novara 21
Siena 20
Ferrara 19
Prato 19
Abbiategrasso 18
Legnano 18
Redmond 18
Mestre 17
Mumbai 17
Ravenna 17
Trento 17
Duino-Aurisina 16
Rimini 16
Torre Del Greco 16
Bolzano 15
Reggio Emilia 15
Dalmine 14
Lugano 14
Quartu Sant'elena 14
Rende 14
San Mateo 14
Scafati 14
Alessandria 13
Asti 13
Bacoli 13
Brussels 13
Buffalo 13
Misterbianco 13
Piacenza 13
Rozzano 13
Sesto San Giovanni 13
Totale 9.210
Nome #
Valutazione quantitativa di Ki-67 nel carcinoma mammario: comparazione tra lettura al microscopio ottico e lettura con analizzatore automatico 20.309
Advances in systemic therapy for metastatic breast cancer: future perspectives 298
Prognostic-predictive factors in breast cancer: comparison of mRNA level (Target Print) and immunohistochemistry expression 181
Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy as an innovative approach. 170
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score 152
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial 144
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. 139
Breast cancer in elderly women: a different reality? Results from the NORA Study 133
Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study 131
Gene expression profiling in breast cancer: A clinical perspective 131
Role of lifestyles in breast cancer risk: a retrospective analysis of Trieste's female population 130
The burden of renal cell cancer: A retrospective longitudinal study on occurrence, outcomes and cost using an administrative claims database 121
Adjuvant systemic treatment of early breast cancer: The NORA study. 120
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. 118
Psychological Response to Cancer: Role of 5-HTTLPR Genetic Polymorphism of Serotonin Transporter 115
A Phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer. 112
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancerdeath: meta-analysis of individual patient data for 10,801 women in 17 randomised trials 112
Tamoxifen versus surgery plus Tamoxifen as primary treatment for elderly patients with breast cancer: combined data from the “GRETA” and “CRC” trials 110
The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study. 107
Identification and Validation of a New Set of Five Genes for Prediction of Risk in Early Breast Cancer 106
Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study 105
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 103
Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study. 102
Sequential Tamoxifen and Aminoglutethimide Versus Tamoxifen Alone in the Adjuvant Treatment of Postmenopausal Breast cancer Patients: Results of an Italian Cooperative Study 99
Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives (Medical Oncology, (2017), 34, 7, (119), 10.1007/s12032-017-0975-5) 97
Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs 94
Early detection of breast cancer recurrences through periodic follow up - Is it useless? 93
La metanalisi di Oxford del 2000: riflessioni e commenti 93
Molecular targets of cancer chemotherapy 90
ITALIAN BREAST CANCER ADJUVANT CHEMO-HORMONE THERAPY COOPERATIVE GROUP TRIALS 90
Changes in adjuvant treatment of early breast cancer in Italy between 2000 and 2008. The NEMESI study versus the NORA study. 87
Chemotherapy vs Tamoxifen vs Chemotherapy + Tamoxifen in Node-positive, Oestrogen-receptor positive Breast Cancer Patients. An update at 7 years of the 1st GROCTA Trial. 83
Annual Hazard Rates of Recurrence for early breast cancer. What has changed in the last 10 years? Results from the NORA study. 83
Effectiveness of magnetotheraphy in resolution of some early complications of the mastectomy operation. 80
An induction dose of epoietin alpha of 40.000 IU daily for three consecutive days increases and mantains hemoglobin levels in anemic cancer patients undergoing chemotherapy. 79
A multicentre, double blind, randomised trial comparing ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis 78
Modulating effect of Lonidamine on Response to Doxorubicin in Metastatic Breast cancer patients: Results from a Multicenter Prospective Randomized Trial. 78
The combination of Metoclopramide, Methylprednisolone and Ondansetron against antiblastic - delayed emesis: a randomised Phase II study. 77
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 74
Gli antidoti in Oncologia medica: efficacia, costo e beneficio 72
Un programme de réhabilitation chez la femme mastectomisée 71
Prevention of chemotherapy-induced early menopause in early breast cancer patients. A phase III multicenter study of GIM Group 70
Cancro del fegato: possibilità di diagnosi precoce 69
Il Carcinoma del Fegato: Realtà e Prospettive Epidemiologia 68
Ovarian function in premenopausal women affected by breast cancer: the measurement of glucuronoconjugate metabolites of 17-beta-estradiol and progesterone throughout one entire menstrual cycle 65
Extragonadal Germ Cell Tumor: a Clinical Stdy. 64
La communication du diagnostic de cancer 64
Carcinoma dell’ovaio 63
Chemotherapy vs Tamoxifen vs Chemotherapy + Tamoxifen in Node-positive, Oestrogen-receptor positive Breast Cancer Patients. An update at 8 years of the first GROCTA (Italian Cooperative Group for Adjuvant Chemo-Hormonal Therapy of Breast cancer)Trial. 61
Corrigendum to "Gene expression profiling in breast cancer: A clinical perspective" [The Breast 22 (2013) 109-120 [doi:10.1016/j.breast.2013.01.016.]] 59
Tamoxifen or Surgery plus Tamoxifen as primary treatment for elderly patients with operable breast cancer: the G.R.E.T.A. Trial 55
Observer variations in mammary thermography: results of a teaching file test carried out in four different centers 54
Effect of menstrual status on response to adjuvant chemotherapy and /or endocrine therapy. 54
Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long term results of the phase III randomized controlled multicenter “GRETA” trial. 50
Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials. 50
Relapse rate after adjuvant trastuzumab in the northeast of Italy: Preliminary data from a multicenter observational study in a clinical setting. J Clin Oncol 30, 2012 (suppl; abstr 586) 48
Factors influencing the switch from tamoxifen to aromatase inhibitors as adjuvant therapy in early breast cancer patients. Results from the NORA Study 47
Prolonged Tamoxifen Treatment of Early Breast Cancer: The experience of the Italian Cooperative Group for Chemo-Hormonal Therapy of Early Breast Cancer. 41
Role of erythropoietin in the oncology patient: critical review of the literature 41
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 32
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer 29
Totale 25.851
Categoria #
all - tutte 36.551
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.551


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.444 0 359 503 607 484 593 530 498 256 192 244 178
2020/20212.813 281 286 258 311 196 227 171 214 226 253 185 205
2021/20221.895 112 142 124 154 121 95 101 110 211 171 169 385
2022/20234.469 323 320 351 347 367 472 293 369 427 284 451 465
2023/20243.525 447 401 315 332 273 185 351 326 76 289 283 247
2024/2025373 274 99 0 0 0 0 0 0 0 0 0 0
Totale 25.851